ReviewSkin health and disease2026
Dupilumab for the treatment of pemphigoid gestationis in the setting of breastfeeding: a case report and review of the literature.
Review in Skin health and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pemphigoid gestationis (PG) is a rare blistering dermatosis usually seen in the second and third trimesters of pregnancy. Treatment of PG is aimed towards the relief of pruritus and prevention of new lesions from developing, often involving high-potency topical corticosteroids, antihistamines, oral corticosteroids and other systemic immune modulators for patients with symptoms of greater severity. Recently, dupilumab, a monoclonal antibody against the alpha subunit of the interleukin-4 receptor, has been used successfully in bullous pemphigoid. We discuss the case of a 34-year-old Asian woman at 32 weeks' gestation who presented with progressive and severely pruritic oedematous urticarial plaques and patches dispersed across the trunk and extremities, with scattered tense bullae. A skin biopsy confirmed the diagnosis of PG. The patient was placed on high-dose oral corticosteroids and concomitant topical steroids, with minimal resolution after attempts to taper oral steroids over the next 4 weeks. Oral prednisone was continued at 17.5 mg for the remainder of her pregnancy given the risks associated with higher dosages. After delivery, the patient's disease worsened, requiring an increase in prednisone. Given that the patient was breastfeeding, dupilumab was initiated as a steroid-sparing agent allowing patient to be tapered off prednisone with significant improvement and control of her disease. The safety of dupilumab for infants who are being breastfed remains under discussion. Herein, we discuss the existing literature and considerations regarding pregnancy and breastfeeding for patients with PG on dupilumab.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.